Virtu KCG Holdings’s Lineage Cell Therapeutics LCTX Stock Holding History

Virtu KCG Holdings’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$106K	Sell	38,515 -55,320	-59%	-$155K	﹤0.01%	2399
2017 Q1	$283K	Buy	93,835 +78,390	+508%	+$223K	0.01%	2016
2016 Q4	$49K	Buy	15,445 +1,751	+13%	+$5.38K	﹤0.01%	3090
2016 Q3	$47K	Sell	13,694 -44,652	-77%	-$123K	﹤0.01%	2791
2016 Q2	$133K	Buy	+58,346	New	+$143K	﹤0.01%	2472
2016 Q1	–	Sell	-44,509	Closed	-$147K	–	3276
2015 Q4	$147K	Buy	44,509 +26,994	+154%	+$80.7K	﹤0.01%	2866
2015 Q3	$42K	Sell	17,515 -97,779	-85%	-$253K	﹤0.01%	3031
2015 Q2	$338K	Buy	115,294 +99,324	+622%	+$385K	0.01%	1921
2015 Q1	$64K	Buy	+15,970	New	+$55.3K	﹤0.01%	2769
2014 Q4	–	Sell	-86,618	Closed	-$220K	–	4013
2014 Q3	$220K	Buy	86,618 +27,651	+47%	+$66.6K	﹤0.01%	2792
2014 Q2	$145K	Buy	+58,967	New	+$133K	﹤0.01%	3179
2014 Q1	–	Sell	-87,700	Closed	-$255K	–	3816
2013 Q4	$255K	Buy	+87,700	New	+$265K	﹤0.01%	2821

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MHP

Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return

DWM

Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Virtu KCG Holdings's LCTX Position: Q2 2017 in Review

Virtu KCG Holdings reduced its Lineage Cell Therapeutics (LCTX) stake by 59% in Q2 2017, selling an estimated $155K and leaving 38,515 shares worth $106K. The position accounts for ﹤0.01% of the portfolio, ranked #2399.

Virtu KCG Holdings first reported a position in LCTX in Q4 2013 and has held it in 12 quarters since. The position peaked at $338K in Q2 2015. 109 funds tracked by Wall St. Rank hold LCTX as of Q2 2017.

Virtu KCG Holdings held 38,515 shares of Lineage Cell Therapeutics worth $106K as of Q2 2017.
Virtu KCG Holdings sold 55,320 Lineage Cell Therapeutics shares in Q2 2017, an estimated $155K.
Lineage Cell Therapeutics made up ﹤0.01% of Virtu KCG Holdings's portfolio in Q2 2017, its #2399 holding.
Virtu KCG Holdings first reported a position in Lineage Cell Therapeutics in Q4 2013 and has held it in 12 quarters since.
Virtu KCG Holdings's Lineage Cell Therapeutics position peaked at $338K in Q2 2015.
109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2017.

Based on Virtu KCG Holdings's 13F filing for Q2 2017, filed 11 Aug 2017.